166 Genetically engineered tumor-infiltrating lymphocytes (cytoTIL15) exhibit IL-2-independent persistence and anti-tumor efficacy against melanoma in vivo
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1818575120744054784 |
|---|---|
| author | Gabriel Helmlinger Rachel Burga Stanley Tam Mithun Khattar Scott Lajoie Kyle Pedro Colleen Foley Alonso Villasmil Ocando Jack Tremblay Benjamin Primack Meghan Langley Dan Thornton Emily Brideau Theresa Ross Gwen Wilmes Sunandan Saha Jeremy Tchaicha Dhruv Sethi Michelle Ols Gary Vanasse Shyam Subramanian Jan ter Meulen |
| author_facet | Gabriel Helmlinger Rachel Burga Stanley Tam Mithun Khattar Scott Lajoie Kyle Pedro Colleen Foley Alonso Villasmil Ocando Jack Tremblay Benjamin Primack Meghan Langley Dan Thornton Emily Brideau Theresa Ross Gwen Wilmes Sunandan Saha Jeremy Tchaicha Dhruv Sethi Michelle Ols Gary Vanasse Shyam Subramanian Jan ter Meulen |
| author_sort | Gabriel Helmlinger |
| collection | DOAJ |
| first_indexed | 2024-12-15T00:36:02Z |
| format | Article |
| id | doaj.art-96bcf551331a468aa219481d0e648459 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-12-15T00:36:02Z |
| publishDate | 2021-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-96bcf551331a468aa219481d0e6484592022-12-21T22:41:47ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262021-11-019Suppl 210.1136/jitc-2021-SITC2021.166166 Genetically engineered tumor-infiltrating lymphocytes (cytoTIL15) exhibit IL-2-independent persistence and anti-tumor efficacy against melanoma in vivoGabriel Helmlinger0Rachel Burga1Stanley Tam2Mithun Khattar3Scott Lajoie4Kyle Pedro5Colleen Foley6Alonso Villasmil Ocando7Jack Tremblay8Benjamin Primack9Meghan Langley10Dan Thornton11Emily Brideau12Theresa Ross13Gwen Wilmes14Sunandan Saha15Jeremy Tchaicha16Dhruv Sethi17Michelle Ols18Gary Vanasse19Shyam Subramanian20Jan ter Meulen21Aff3 grid.418152.bEarly Clinical Development, IMED Biotech Unit, AstraZeneca 35 Gatehouse Drive 02451 Waltham MA USANorthwestern University, Chicago, USA4Department of Anesthesia, Scarborough General Hospital, Ontario, CanadaObsidian Therapeutics, Cambridge, MA, USAObsidian Therapeutics, Cambridge, MA, USAObsidian Therapeutics, Cambridge, MA, USAObsidian Therapeutics, Cambridge, MA, USAObsidian Therapeutics, Cambridge, MA, USAObsidian Therapeutics, Cambridge, MA, USAObsidian Therapeutics, Cambridge, MA, USAObsidian Therapeutics, Cambridge, MA, USAObsidian Therapeutics, Cambridge, MA, USAObsidian Therapeutics, Cambridge, MA, USAObsidian Therapeutics, Cambridge, MA, USAObsidian Therapeutics, Cambridge, MA, USAObsidian Therapeutics, Cambridge, MA, USAObsidian Therapeutics, Cambridge, MA, USAObsidian Therapeutics, Cambridge, MA, USAObsidian Therapeutics, Cambridge, MA, USAObsidian Therapeutics, Cambridge, MA, USAObsidian Therapeutics, Cambridge, MA, USAObsidian Therapeutics, Cambridge, MA, USA |
| spellingShingle | Gabriel Helmlinger Rachel Burga Stanley Tam Mithun Khattar Scott Lajoie Kyle Pedro Colleen Foley Alonso Villasmil Ocando Jack Tremblay Benjamin Primack Meghan Langley Dan Thornton Emily Brideau Theresa Ross Gwen Wilmes Sunandan Saha Jeremy Tchaicha Dhruv Sethi Michelle Ols Gary Vanasse Shyam Subramanian Jan ter Meulen 166 Genetically engineered tumor-infiltrating lymphocytes (cytoTIL15) exhibit IL-2-independent persistence and anti-tumor efficacy against melanoma in vivo Journal for ImmunoTherapy of Cancer |
| title | 166 Genetically engineered tumor-infiltrating lymphocytes (cytoTIL15) exhibit IL-2-independent persistence and anti-tumor efficacy against melanoma in vivo |
| title_full | 166 Genetically engineered tumor-infiltrating lymphocytes (cytoTIL15) exhibit IL-2-independent persistence and anti-tumor efficacy against melanoma in vivo |
| title_fullStr | 166 Genetically engineered tumor-infiltrating lymphocytes (cytoTIL15) exhibit IL-2-independent persistence and anti-tumor efficacy against melanoma in vivo |
| title_full_unstemmed | 166 Genetically engineered tumor-infiltrating lymphocytes (cytoTIL15) exhibit IL-2-independent persistence and anti-tumor efficacy against melanoma in vivo |
| title_short | 166 Genetically engineered tumor-infiltrating lymphocytes (cytoTIL15) exhibit IL-2-independent persistence and anti-tumor efficacy against melanoma in vivo |
| title_sort | 166 genetically engineered tumor infiltrating lymphocytes cytotil15 exhibit il 2 independent persistence and anti tumor efficacy against melanoma in vivo |
| work_keys_str_mv | AT gabrielhelmlinger 166geneticallyengineeredtumorinfiltratinglymphocytescytotil15exhibitil2independentpersistenceandantitumorefficacyagainstmelanomainvivo AT rachelburga 166geneticallyengineeredtumorinfiltratinglymphocytescytotil15exhibitil2independentpersistenceandantitumorefficacyagainstmelanomainvivo AT stanleytam 166geneticallyengineeredtumorinfiltratinglymphocytescytotil15exhibitil2independentpersistenceandantitumorefficacyagainstmelanomainvivo AT mithunkhattar 166geneticallyengineeredtumorinfiltratinglymphocytescytotil15exhibitil2independentpersistenceandantitumorefficacyagainstmelanomainvivo AT scottlajoie 166geneticallyengineeredtumorinfiltratinglymphocytescytotil15exhibitil2independentpersistenceandantitumorefficacyagainstmelanomainvivo AT kylepedro 166geneticallyengineeredtumorinfiltratinglymphocytescytotil15exhibitil2independentpersistenceandantitumorefficacyagainstmelanomainvivo AT colleenfoley 166geneticallyengineeredtumorinfiltratinglymphocytescytotil15exhibitil2independentpersistenceandantitumorefficacyagainstmelanomainvivo AT alonsovillasmilocando 166geneticallyengineeredtumorinfiltratinglymphocytescytotil15exhibitil2independentpersistenceandantitumorefficacyagainstmelanomainvivo AT jacktremblay 166geneticallyengineeredtumorinfiltratinglymphocytescytotil15exhibitil2independentpersistenceandantitumorefficacyagainstmelanomainvivo AT benjaminprimack 166geneticallyengineeredtumorinfiltratinglymphocytescytotil15exhibitil2independentpersistenceandantitumorefficacyagainstmelanomainvivo AT meghanlangley 166geneticallyengineeredtumorinfiltratinglymphocytescytotil15exhibitil2independentpersistenceandantitumorefficacyagainstmelanomainvivo AT danthornton 166geneticallyengineeredtumorinfiltratinglymphocytescytotil15exhibitil2independentpersistenceandantitumorefficacyagainstmelanomainvivo AT emilybrideau 166geneticallyengineeredtumorinfiltratinglymphocytescytotil15exhibitil2independentpersistenceandantitumorefficacyagainstmelanomainvivo AT theresaross 166geneticallyengineeredtumorinfiltratinglymphocytescytotil15exhibitil2independentpersistenceandantitumorefficacyagainstmelanomainvivo AT gwenwilmes 166geneticallyengineeredtumorinfiltratinglymphocytescytotil15exhibitil2independentpersistenceandantitumorefficacyagainstmelanomainvivo AT sunandansaha 166geneticallyengineeredtumorinfiltratinglymphocytescytotil15exhibitil2independentpersistenceandantitumorefficacyagainstmelanomainvivo AT jeremytchaicha 166geneticallyengineeredtumorinfiltratinglymphocytescytotil15exhibitil2independentpersistenceandantitumorefficacyagainstmelanomainvivo AT dhruvsethi 166geneticallyengineeredtumorinfiltratinglymphocytescytotil15exhibitil2independentpersistenceandantitumorefficacyagainstmelanomainvivo AT michelleols 166geneticallyengineeredtumorinfiltratinglymphocytescytotil15exhibitil2independentpersistenceandantitumorefficacyagainstmelanomainvivo AT garyvanasse 166geneticallyengineeredtumorinfiltratinglymphocytescytotil15exhibitil2independentpersistenceandantitumorefficacyagainstmelanomainvivo AT shyamsubramanian 166geneticallyengineeredtumorinfiltratinglymphocytescytotil15exhibitil2independentpersistenceandantitumorefficacyagainstmelanomainvivo AT jantermeulen 166geneticallyengineeredtumorinfiltratinglymphocytescytotil15exhibitil2independentpersistenceandantitumorefficacyagainstmelanomainvivo |